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Abstract: The use of selectable markers (ecogpt) and selection pressures to aid in detection 
of  poxvirus  (Vaccinia,  VV)  recombinants  has  been  implicated  in  the  unintended 
introduction of second site mutations. We have reinvestigated the use of the helper virus 
system  described  by  Scheiflinger  et  al.  [1]  and  adapted  by  Yao  and  Evans  [2]  which 
produces recombinants at a high frequency in the absence of any selection, at a rate of  
6–100%. Our system uses fowlpox virus (FPV) as the infectious helper virus which in 
infected  cells  provides  the  enzymatic  apparatus  for  transcription  and  replication  of  a 
purified, transfected VV genome and for recombination with a second transfected PCR 
generated DNA fragment. To optimize the system, a PCR DNA fragment was generated 
that contained poxvirus promoter driven gfp and lacZ genes inserted within the coding 
sequences  of  the  viral  thymidine  kinase  gene.  This  PCR  fragment  was  co-transfected 
together with VV genomic DNA. Recombinant VV was identified by plaquing the mixture 
on  cells  non-permissive  for  FPV  and  selection  of  green  fluorescent  or  LacZ  positive 
recombinant  vaccinia  plaques.  The  system  was  optimized  using  FPV  permissive  cells 
(CEF) and non-permissive cells (A549, CV-1) for both the initial infection/transfection and 
the subsequent selection. Up to 70% of the progeny vaccinia virus contained the gfp/LacZ 
insertion. In order to test for the presence of FPV/VV intertypic recombinants or other 
unintended mutations, recombinant wtVV (RwtVV) was regenerated from the gfp/LacZ 
viruses and evaluated by RFLP analysis and pathogenesis in animals. While all RwtVVs 
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were viable in cell culture, in many of the RwtVV isolates, RFLP differences were noted 
and while some recombinant viruses exhibited wild type behavior in mice, a wide range of 
virulence  indicative  of  unintended  changes  suggests  that  mutants  created  by  “rescue” 
systems  require  careful  analysis  particularly  before  use  for  in  vivo  studies  employing 
animal models. 
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1. Introduction 
The generation of recombinant poxviruses is essential for determining the role of individual genes 
in virus growth and pathogenesis. This technology is critical for the field of poxvirus biology and thus 
a  number  of  elegant  reports  have  addressed  the  most  efficient  method  of  generating  recombinant 
viruses  [2–6].  Although  there  is  a  long  history  of  fine  tuning  the  methodology  for  generating 
recombinant  poxviruses,  the  same  protocols  with  few  modifications  have  been  used  for  decades 
[2,3,5,7–10].  The  fine  tuning  has  involved  the  optimization  of  length  of  homologous  nucleotide 
sequences  necessary  for  recombination  to  occur  and  the  benefits  of  linear  DNA  as  compared  to 
plasmid DNA used in the reactions [9–17].  
Historically,  the  generation  of  recombinant  poxviruses  has  been  labor  and  time  intensive.  The 
historical  method  for  generating  recombinant  orthopoxviruses  involved  transfecting  plasmid  DNA 
containing  the  target  mutation  in  cells  infected  with  the  parent  virus,  allowing  for  homologous 
recombination  to  occur  and  then  purifying  the  desired  virus.  This  method  required  not  only  the 
generation of the plasmid containing the target mutation but multiple rounds of plaque purification 
screenings to produce the desired virus recombinant. Such methods for generating recombination in a 
nonessential  gene  can  be  relatively  inefficient,  generating  below  1%  recombinant  viruses  at  the 
beginning  of  the  plaque  purification  screening  [11,15].  This  low  rate  of  recombination  has  been 
observed out of the infection/transfection reaction regardless of the manipulation of variables such as 
the viral multiplicity of infection (MOI) and amount of plasmid DNA transfected. 
The low rate of recombinant virus generation can be increased dramatically by the use of selectable 
markers such as ecogpt [18–22]. Selectable markers are advantageous in the ease and time required in 
which  recombinant  viruses  can  be  identified.  However,  the  use  of  selectable  markers  has  been 
implicated  in  causing  secondary  mutations  elsewhere  in  the  genome  not  obvious  until  the  virus 
revertant is generated and analyzed [23]. While viruses with secondary site mutations may not exhibit 
altered properties in a cell culture based system, those mutations may produce unexpected phenotypes 
when such viruses are used in animal models. 
Previous helper virus systems have used orthopox, leporipox and avipox viruses as helper viruses 
with transfected fragmented target rescue virus genomes and a linear DNA fragment containing the 
desired  mutation  [1,2,24,25].  These  systems  relied  on  the  helper  virus  to  provide  the  machinery 
necessary to assemble the fragmented genome while simultaneously integrating the targeted mutation. 
While the rate of recombinants generated was near 100% in these studies, the generation of digested 
fragmented virus genomes is labor intensive and requires the desired mutation to fall near a restriction Viruses 2011, 3                         
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enzyme site for efficient recombinant virus generation [1,2,24,25]. Therefore, each recombinant virus 
requires a great deal of in silico strategy and planning before attempting to generate the desired virus. 
In an era that values the high throughput systems this procedure is not desirable and outdated. 
Here we describe a system similar to that used by Yao and Evans [25] to generate high rates of 
recombinant viruses. This system uses fowlpox virus (FPV) as the helper virus in infected cells which 
are transfected with intact vaccinia virus (VV) wildtype genomic DNA together with a PCR generated 
DNA fragment containing the mutation of choice. The FPV helper virus system supplies the enzymatic 
machinery  needed  for  recombination  and  also  allows  rescue  and  production  of  infectious  VV 
[1,26,27].  FPV  was  chosen  to  rescue  orthopoxvirus  genomes  due  to  its  narrow  host  range  [28], 
infecting mammalian cells but only replicating in avian cells, allowing for elimination of FPV from the 
orthopoxvirus mixtures by plaquing on mammalian cells. 
To avoid the standard time consuming procedures required to generate recombinant orthopoxviruses 
via the classical method and the problems implicated by the use of selectable markers in generating 
recombinant viruses, we sought a simple, reproducible method for generating recombinants at a high 
frequency without the use of selection pressures. The procedure we describe results in generation of 
desired mutations at a frequency of 70%. While generating high levels of recombinant viruses quickly 
is  advantageous,  we  further  took  steps  to  analyze  whether  the  resulting  virus  isolates  exhibited 
unintended mutations and pathogenesis which differed from that of the parent VV. 
2. Results and Discussion 
2.1. Generation of VV in FPV Permissive cells 
To evaluate and optimize the helper virus system, we began by assessing the ability of fowlpox 
virus (FPV) to produce infectious vaccinia virus (VV) from FPV infected cells transfected with VV 
genomic  DNA  with  or  without  transfected  VV  PCR  generated  DNA  fragments.  The 
infection/transfection rescue scheme for all conditions tested in this report is depicted in Figure 1. Our 
initial transfections were done in chicken embryo fibroblast (CEF) cells which are permissive for FPV 
growth [28].  
In order to optimize the generation of recombinant VV using FPV, we first ensured that we could 
obtain viable VV from this helper virus system, and optimized the yield of VV prior to generating any 
recombinant viruses. The first condition optimized was the ratio of transfection reagent to DNA in 
FPV infected cells. CEF cells were infected with FPV at an MOI of 1 or 25 and transfected with 12 µg 
of intact genomic VV DNA while varying the amount of cationic transfection reagent Lipofectamine 
2000. Lipofectamine 2000 serves to facilitate the DNA delivery and uptake via endocytosis [29,30]. A 
1:1  ratio  of  total  µg  DNA  to  µL  of  transfection  reagent  was  ultimately  confirmed  as  the  best 
DNA:detergent ratio for all future experiments, and this ratio was in agreement with manufacturer 
recommendations (Figure 2a). 
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Figure 1. Infection/transfection scheme for generation of recombinant vaccinia virus. Cells 
are infected with fowlpox virus (FPV) and transfected with genomic vaccinia virus (VV) 
DNA ± a disrupted VV PCR fragment containing the desired mutation (lacZ or gfp). The 
resulting  virus  mixture  is  then  plaqued  on  mammalian  cells  to  eliminate  FPV  and  the 
desired viruses isolated. 
 
 
There were few differences in the total virus amount recovered between the reactions using 4, 8 or 
12 µL of Lipofectamine 2000 at either FPV multiplicity of infection. At high volumes of transfection 
reagent, the virus titer decreased slightly, most likely caused by cytotoxicity typical of high doses of 
cationic lipids [31–33]. In our hands, 12 µL of the transfection reagent together with 12 µg of total 
DNA was selected as optimal for all future experiments.  
When the cells were infected with FPV at an MOI of 1, the total VV recovered was somewhat 
higher than when the cells were infected at an MOI of 25 (Figure 2a). However, this increase may be 
attributed to a secondary amplification of rescued VV leading to infection of cells not initially infected 
by FPV at the lower multiplicity. In order to ensure that all the cells in the cell monolayer  were 
initially infected by FPV while minimizing any secondary amplification of VV, FPV at an MOI of 25 
was used for all future experiments.  
When  an  infection/transfection  mixture  harvested  from  CEF  cells  was  plaqued  on  a  cell  line 
nonpermissive to FPV such as CV-1 cells and stained with Crystal Violet, a total of over 10
7 plaques 
were observed consisting of both large and small plaques (Figure 2b). Typically, the ratio of large to 
small plaques was roughly 2:1 upon plaquing of the initial infection/transfection mixture on CV-1 
cells. The large plaques were typical of wtVV plaques. However, the heterogeneity could have arisen 
in part from FPV/VV intertypic recombinants, partially defective VV or plaques of mixed genotypes. 
Visualization of the infection/transfection mixture via plaque assay demonstrated that a majority of 
plaques, independent of size, were GFP positive. Upon sequential passage on a FPV nonpermissive 
cell line, CV-1, the number of small plaques decreased and eventually disappeared all together by the 
second or third passage. Plaques most similar to those of wtVV were chosen for further studies. 
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Figure  2.  Optimization  of  transfection  reagent  for  rescue  of  infectious  vaccinia  virus 
particles. (a) Titers of VV rescued from chicken embryo fibroblast (CEF) cells infected 
with FPV at two different FPV MOI and transfected with 12 µg VV genomic DNA using 
varying amounts of transfection reagent Lipofectamine 2000. (b) Crystal Violet staining of 
the initial infection/transfection mixture plaqued on CV-1 cells. Plaquing on CV-1 cells of 
VV rescued from CEF cells infected with FPV at an MOI of 25. 
 
2.2. Generation of Recombinant VV 
The system was next evaluated for the ability to generate high levels of VV recombinants as a 
function  of  genome/PCR  DNA  fragment  ratios.  To  determine  rates  of  recombination,  a  
PCR-generated  3,438  bp  fragment  containing  gfp  and  lacZ  under  the  poxvirus  PE/L  and  P7.5, 
respectively, flanked by TK gene sequence was used. The gfp and lacZ genes allow for ready detection 
of recombinants [3,6,7,34]. 
The  process  of  optimizing  the  generation  of  recombinant  VV  was  performed  using  conditions 
optimal for FPV mediated rescue of VV as described and shown in Figure 2. CEF cells were infected 
with FPV at an MOI of 25 and co-transfected with a total of 12 µg DNA, using genomic VV DNA and 
gfp/lacZ PCR fragment at varying ratios. Mass ratios of genomic DNA to fragment DNA of 1:20, 1:10, 
1:1, 10:1 and 20:1 were used to determine the optimal ratio for generation of recombinant VV. The 
resulting infection/transfection mixtures were plaqued on CV-1 cells and analyzed for the number of 
LacZ positive plaques relative to the total number of plaques obtained. 
At all ratios tested recombinant VV was obtained (Figure 3), however the percent of recombinant 
VV was highly dependent on the ratio of VV DNA: gfp/lacZ PCR fragment. The highest numbers of 
recombinant VV were observed when the ratio of genomic DNA:gfp/lacZ PCR fragment was 1:10. At 
this ratio greater than 80% of the total resulting VV viruses were recombinants. While these ratios are 
based upon total mass of DNA added, the ratio of copy numbers is much higher, with the gfp/lacZ 
PCR fragment being in substantial excess compared to that of genomic VV copy number, and is 
theorized to force the recombination between the VV DNA and gfp/lacZ PCR fragment. 
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Figure 3. Frequency of VV lacZ/gfp recombinant viruses from optimization of ratio of 
genomic DNA to gfp/lacZ PCR fragment in CEF cells. Cells were infected with FPV at an 
MOI of 25 and transfected with a total of 12 µg DNA in the ratios noted in the graph. Error 
bars represent SEM; n = 10. 
 
2.3. The Use of Cells Non-Permissive for FPV to Rescue VV 
Although  high  numbers  of  infectious  VV  and/or  VV  recombinants  were  generated  in  FPV 
permissive cells, as was noted in Figure 2, the infection/transfection mixture produces heterogenous 
plaque sizes consistent with the formation of significant numbers of VV variants or even FPV/VV 
intertypic recombinants (Figure 1b). Therefore, a cell line that supported the generation of recombinant 
VV while limiting FPV growth was desirable. 
FPV has a limited host range restricted to avian cells but will infect mammalian cells in an abortive 
manner  [8,35,36].  Based  upon  this  host  restriction,  the  mammalian  cell  line  A549  was  tested  for 
support of FPV growth using a low multiplicity growth curve (Figure 4). There was no virus growth of 
FPV on A549 cells whereas the yield of FPV from CEF cells was 10
8 pfu within 48 hours. Given that 
FPV does not replicate on A549 cells, we then tested whether A549 cells could be utilized for rescuing 
transfected genomic VV DNA and generating recombinant VV in an attempt to limit the amount of 
FPV produced during the infection/transfection. 
Again,  after  confirmation  that  FPV  infected  A549  cells  would  support  rescue  of  transfected 
genomic VV, the conditions for generating recombinant VV were optimized as initially described in 
Figure 1. Once again, we observed that FPV was readily able to rescue intact genomic VV DNA to 
produce infectious VV as indicated by the ability to plaque on CV-1 cells. The conditions were again 
optimized  using  A549  cells  for  the  MOI  of  FPV  and  ratio  of  transfection  reagent  to  total  DNA 
transfected of genomic DNA (Figure 5a). The optimal conditions were the same as those determined 
for the CEF cells in which FPV at an MOI of 25 and a ratio of 1:1 v/mass for Lipofectamine 2000: 
genomic DNA. 
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Figure 4. Growth of FPV on permissive CEF cells and non-permissive A549 cells. Cells 
were infected with FPV at an MOI of 0.001, harvested at 0, 24, 48, 72 and 96 hours post 
infection, and titered on CEF cells. 
 
Figure  5.  Optimization  of  transfection  reagent  for  rescue  of  infectious  vaccinia  virus 
particles using A549 cells. A549 cells were infected with FPV at an MOI of 1 or 25 and 
transfected  with  genomic  VV  DNA  at  varying  concentrations  of  Lipofectamine  2000.  
(a) Rescue of VV in A549 cells using varying amounts of transfection reagent and 12 µg 
VV DNA at a low (1) and a high (25) MOI of FPV. Error bars represent SEM. (b) Plaquing 
stained with crystal violet on CV-1 cells of resulting virus mixture from VV rescued in 
A549 cells infected with FPV at an MOI of 25. 
 
We then analyzed the ability of FPV infected A549 cells to produce VV recombinants following 
transfection with both VV intact DNA and the PCR fragment encoding gfp/lacZ in the same fashion as 
shown in Figure 2. These results are shown in Figure 6. As in CEFs, the maximum percentage of 
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recombinant viruses was obtained when using a mass ratio of 1:10 genomic VV DNA to gpf/lacZ PCR 
fragment DNA, with an average yield of 50% rescued viruses being recombinant VV. Importantly, 
infection/transfection  of  A549  cells  produced  far  lower  backgrounds  of  small  plaques  than  were 
observed in infected/transfected CEF cells (compare Figures 2b and 5b) with 2 × 10
5 VV plaques  
and 4 × 10
5 small plaques observed upon plaquing of the infection/transfection reaction. By using 
A549  cells  for  the  infection/transfection,  the  number  of  small  plaques  was  decreased  by  10-fold 
allowing for better visualization and separation of the desired plaques. The comparative differences in 
plaque  morphology  between  CEF  cells  and  A549  cells  indicate  a  clear  cell  line  dependence 
on outcome.  
Figure 6. Frequency of VV lacZ/gfp recombinant viruses generated from FPV infected 
A549 cells. A549 cells were infected with an MOI of 25 and transfected with 12 µg of total 
DNA  in  the  ratios  shown  using  12  µL  of  transfection  reagent.  The  percentages  of 
recombinant viruses were determined by staining for the presence of LacZ and counting the 
number of LacZ positive plaques in relation to the total number of plaques. Error bars 
represent SEM. N = 4. 
 
2.4. Analysis of Resulting Viruses for Unintended Mutations and Pathogenicity 
Although many of the presumed vaccinia viruses generated using the FPV helper virus system 
produced plaques similar in size to those of wtVV and behaved as such in cell culture, more stringent 
tests were needed to ascertain whether these recombinants were truly “wild type virus” in all respects 
except for the newly introduced gene. To address this issue, the recombinant viruses containing the 
gfp/lacZ marker gene were reverted back to wild type using the FPV system. This was accomplished 
by  taking  several  individual  VV  recombinant  isolates  derived  from  different  infection/transfection 
reactions and first purifying the recombinant VV DNA using the same procedures as for the wtVV 
DNA. This recombinant VV DNA was then used in the FPV mediated infection/transfection system of 
infected A549 cells as described above together with a PCR generated wild type TK gene fragment. 
The resulting viruses are referred to as rescued recombinant wtVV (RwtVV) and were plaque purified, 
selecting for the absence of gfp/lacZ and used for pathogenesis as well as an analysis of differential 
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plaquing efficiency and random alterations in overall sequence by restriction length polymorphism 
(RFLP)  analysis  [37].  It  is  important  to  note  that  all  viruses  were  easily  isolated,  requiring  
only three rounds of plaque purification. 
Nine separate RwtVV isolates were used for in vivo analysis of virulence in C57BL/6 mice. Groups 
of  three  animals  were  inoculated  via  intratracheal  injection  with  10
6  and  10
7  pfu  for  each  of  the 
RwtVV  isolates  and  compared  to  animals  infected  with  wtVV.  Animal  health  was  assessed  daily 
including body temperature, weight loss and overall appearance. Animals were euthanized if their 
body temperature decreased from a normal of 36 °C to 30 °C or lower or if they experienced weight 
loss of greater than 30% of initial body weight. Typically, a dose of 10
6 pfu of wtVV is 100% lethal in 
C57BL/6  mice,  accompanied by significant weight  loss and other  clinical symptoms  necessitating 
euthanasia within 6 to 8 days post infection [38].  
The RwtVV in vivo phenotypes relative to wtVV phenotypes are reported in Table 1. Two of the 
nine isolates (RwtVV 3 and 6) exhibited a phenotype identical to that of wtVV with all animals at both 
10
6 and 10
7 pfu doses requiring euthanasia due to severe disease. Three of the nine isolates exhibited 
attenuation at the 10
6 pfu dose but lethal disease at the 10
7 pfu dose, thereby being classified as viruses 
that were attenuated by 1 log (RwtVV 5, 8 and 9). RwtVV 7 was classified as 2 logs attenuated in 
which all the mice at the 10
6 pfu dose were relatively unaffected while the animals at 10
7 pfu exhibited 
moderate disease. Three of the nine viruses were completely attenuated with all animals at both doses 
exhibiting few or no disease symptoms at all (RwtVV 1, 2 and 4). 
Table 1. In vitro and in vivo evaluation of rescued wildtype VV (RwtVV). Isolates were 
inoculated intratracheally into C57BL/6 mice at 10
6 or 10
7 pfu and monitored for severe 
disease as compared to wtVV infected animals. The viruses were also plaqued on CV-1 
and  PK-15  cells  and  the  ratio  of  plaques  on  CV-1:PK-15  calculated  as  a  measure  of 
viral fitness. 
Virus Isolate  Phenotype in Mice 
CV-1:PK-15 Plaquing 
Efficiency Ratio 
RwtVV 1  <2 logs attenuated  80 
RwtVV 2  <2 logs attenuated  79074 
RwtVV 3  wild type  21 
RwtVV 4  <2 logs attenuated  275 
RwtVV 5  1 log attenuated  20 
RwtVV 6  wild type  16 
RwtVV 7  2 logs attenuated  1084 
RwtVV 8  1 log attenuated  9074 
RwtVV 9  1 log attenuated  36 
wtVV  wild type  23 
 
Given the variation of the RwtVV virus isolates in mice, further in vitro examination of the isolates 
was performed. The goal was to determine if the relative pathogenesis in animals could be predicted 
via cell culture based assays as a time and cost effective evaluation of the produced viruses. For this 
assay, we evaluated relative plaquing efficiencies of the viruses on mildly restrictive CV-1 cells and 
highly  restrictive  PK-15  cells,  which  are  among  the  most  restrictive  cell  lines  for  vaccinia  virus, Viruses 2011, 3                         
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tolerating fewer deleterious mutations than other cell lines routinely utilized [39]. All the RwtVV 
isolates that exhibited a phenotype comparable to that of wtVV had CV-1:PK-15 plaquing ratios of 
less than 50, similar to that of wtVV (Table 1). The ratios of all the other viruses did not correlate well 
with  pathogenesis  predictions  in  mice;  several  completely  apathogenic  isolates  (Rwt1  and  4)  had 
relatively low ratios of 80 and 275, respectively, while RwtVV 8 exhibited 1 log attenuation in mice 
and had a ratio of 9074. These results suggest that recombinant viruses that exhibit relative plaquing 
ratios greater than that of wtVV are at a higher risk for behaving aberrantly in an in vivo evaluation. 
RwtVV 1 to 5 were also examined by RFLP analysis at the Center for Disease Control to detect 
changes in genome sequence that could account for the variation in pathogenicity observed. The RFLP 
analysis examined the genomes via restriction digestion patterns of 20 segments crossing the genomes. 
All RwtVV isolates that exhibited attenuation in mice had significant polymorphisms compared to 
wtVV, with  locations  exhibiting any alteration in  RFLP pattern notated  as  a  region  with  changes 
(Figure 7). While there were some locations with less significant changes, again there was no clear 
correlation of banding patterns to pathogenesis. RwtVV 1, 4 and 5 exhibited changes at fragment 10, 
which  is  the  band  in  which  the  TK  gene  is  located,  indicating  the  change  occurred  during 
recombination. The gfp/lacZ viruses from which the RwtVV isolates were derived also underwent 
RFLP analysis and there were few changes observed except for the expected change in fragment 10 
where the TK gene is located, suggesting that the changes accumulate over time with contributions 
from both normal passage of virus in cell culture and recombination with FPV (data not shown). While 
the changes observed in the RFLP analysis were presumed to be due in part to recombination with 
FPV it is not possible to determine which changes were due to routine passage in cell culture. 
Figure 7. Restriction fragment length polymorphism (RFLP) analysis of rescued wild type 
VV. The genomes of the viruses noted in the table underwent RFLP analysis as compared 
to the parental wild type virus. Any changes in banding patterns were noted as a change in 
that section of the genome. Changes for the five selected isolates are noted by a dark blue 
shadowing of the box, no shading represents no changes were detected. For comparison 
purposes the phenotype of the viruses in animals is also shown on the table as previously 
shown in Table 1.  
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3. Experimental Section 
3.1. Cell Culture 
CV-1 and PK-15 cells were maintained in Minimum Essential Media (MEM) with Earle’s Salts 
(Gibco, Grand Island, NY, USA) supplemented with 2 mM glutamine (Media Tech, Herndon, VA, 
USA),  50  U/mL  penicillin  G  and  50  µg/mL  streptomycin  (Media  Tech),  1  mM  sodium  pyruvate 
(Media Tech), and 0.1 mM nonessential amino acids (Media Tech) and 5% v/v FBS (Gibco). 
CEF  cells  were  maintained  in  Media  199  supplemented  with  2  mM  glutamine  (Media  Tech, 
Herndon, VA, USA), 50 U/mL penicillin G and 50 µg/mL streptomycin (Media Tech), 1 mM sodium 
pyruvate  (Media  Tech),  and  0.1  mM  nonessential  amino  acids  (Media  Tech),  and  10%  v/v  FBS 
(Gibco).  
A549  cells  were  maintained  in  Dulbeco’s  Modified  Eagle  Medium  supplemented  with  2  mM 
glutamine  (Media  Tech,  Herndon,  VA,  USA),  50  U/mL  penicillin  G  and  50  µg/mL  streptomycin 
(Media Tech), 1 mM sodium pyruvate (Media Tech), and 0.1 mM nonessential amino acids (Media 
Tech), and 10% v/v FBS (Gibco). 
3.2. Virus Propagation 
VV-WR (wild type VV), VVgfp/lacZ and RwtVV were grown and titered on CV-1 or PK-15 cells 
using standard methods [40,41]. FPV-T7 was grown and tittered on CEF cells using standard methods 
[42]. All viruses for animal infections were pad purified over 36% sucrose using standard methods and 
resuspended in PBS [40,41]. 
3.3. DNA Isolation from Virus 
Virus was placed onto confluent CV-1 150 mm dishes at an MOI of 0.025. The virus was harvested 
4 days post infection by centrifugation at 1430 x g at 4 °C for 10 minutes. The pellet was resuspended 
in 14 mL 14 mM Tris-Cl pH 7.5. The cells were mechanically homogenized via ~ 40 strokes of the 
dounce and centrifuged at 300 x g for 5 minutes at 4 °C. The resulting supernatant was saved and 2 mL 
of 10 Mm Tris-Cl pH7.5 was used to resuspend the pellet. The resuspended pellet was centrifuged at 
300 x g for 5 minutes at 4 °C and the resulting supernatant removed. 
The supernatant underwent protein digestion with 2.45 × 10
–7 mol 2-mercaptoethanol, 0.057 mg 
Proteinase K, 0.114 mmol sodium chloride, and 0.57% sodium dodecyl sulfate at 37 °C for 12 hours. 
The  resulting  mixture  was  then  extracted  twice  with  one  volume  of  STE  saturated 
phenol:chloroform:isoamyl alcohol. Three times the total volume of 200 proof ethanol and 0.3 mM 
sodium acetate pH 7.0 was added. The DNA was then swirled out using a heat sealed sterile pasteur 
pipette and suspended in sterile water. 
3.4. Generation of PCR Fragments 
A plasmid containing gfp under the PE/L promoter and lacZ under the P7.5 promoter flanked by the 
vaccinia virus thymadine kinase gene (TK) named pSC65 gfp lacZ was used to generate the gfp/lacZ 
containing PCR fragment. This plasmid is a modification of pSC65 from the B. Moss laboratory [43]. Viruses 2011, 3                         
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PCR was carried out on pSC65 gfp lacZ using 1.6 U Vent DNA polymerase, 0.3 M of each primer, 
0.5  mM  dNTP,  and  0.2  g  plasmid  DNA,  and  Vent  ThermoPol  Buffer  (New  England  Biolabs, 
Massachusetts, USA). Thermocycler conditions were: 94 C for 3 min; 10 cycles of 94 C for 15 
seconds, 53 C for 30 seconds, 68 C for 5 min; then 30 cycles with no changes except for the addition 
of 5 seconds per cycle to the 68 C step; 68 C for 7 minutes [44]. The primers used for generation of 
the  PCR  fragment  from  the  plasmid  were  IDT131:  GGCGGACATATTCAGTTG  and  IDT132: 
AGTCGATGTAACACTTTC. The overlapping TK gene sections were 250 bp PCR products were 
purified via Edge Biosystems PCR clean up columns per the manufacturer instructions prior to use in 
the transfection reactions. 
The wild type TK gene fragment was amplified from VV-WR genomic DNA using IDT131 and 
IDT132 and subjected to the same purification steps as outlined for the gfp/lacZ PCR fragment. 
3.5. Verification of gfp/LacZ in TK Locus 
DNA of VVgfp/lacZ and RwtVV viruses was isolated using Qiagen DNeasy (Qiagen, California, 
USA) kit per manufacturer directions. PCR of the TK locus was performed using IDT131 and IDT132 
for the presence of a wild type TK band (from wild type genes) of ~ 500 bp and/or gfp/lacZ in the TK 
locus (from knockout viruses) of ~ 5 kbp. The presence of the gfp/lacZ band with no wild type TK 
band by PCR and positive for LacZ and/or GFP was determined sufficient for confirmation of the 
desired virus construct. Alternatively, the presence of a wild type TK band only by PCR and the 
absence  of  GFP  and  LacZ  by  plaque  analysis  staining  were  determined  to  be  sufficient  for 
confirmation of a wild type TK locus virus (data not shown). Should the gfp/lacZ TK fragment had 
integrated into alternative sites in the genome generating revertant viruses would have been difficult to 
generate. This was not observed therefore no further analysis or sequencing was performed. 
3.6. Infection/Transfection 
FPV-T7  was  inoculated  onto  CEF  cells  passage  2  or  A549  passage  10  cells  (2  ×  10
6  cells  
per 35 mm dish) at an MOI of 1 or 25 in an inoculum volume of 0.5 mL. After one hour of absorption 
the virus inoculum was removed and 0.1 mL transfection mixture was added followed by 1 mL of 
growth media without supplements. After 4 hours of incubation in incubators 1ml of complete media 
was added to each infection/transfection reaction. Twenty four hours post infection the mixture was 
harvested, centrifuged at 1300 x g for 20 minutes, and the cell pellets were resuspended in 0.3 mL 
DMEM with 1% HEPES. 
3.7. FPV Growth Curve 
Confluent A549 and CEF cells were inoculated with FPV-T7 at an MOI of 0.001 for 1 hour. The 
innoculum was removed and 2 mL of growth media added to the cells. Cells were isolated at times of 
0, 24, 48, 72, and 96 hours post addition of growth media. The cell pellets were resuspended in media 
with HEPES and titered on CEF cells using standard methods. 
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3.8. Animal Infection and Monitoring 
Infections were performed as previously described [38,45]. Briefly, mice were subjected to general 
anesthesia (isoflurane) prior to inoculation. All mice maintained a surgical plane of anesthesia during 
the procedure. A 3 mm ventromedial incision was made adjacent to the trachea for subcutaneous 
insertion of a microchip used to monitor body temperature and unique animal identification number 
(BioMedic Data Systems, Seaford, DE). A total volume of 30 µL of virus diluted in PBS was injected 
into  the  trachea.  The  incision  was  closed  using  surgical  glue  (Nexaband,  Abbott  Animal  Health, 
Chicago IL). 
Each  animal  was  microchipped  at  the  time  of  infection  to  transmit  body  temperature  and 
identification number to the DAS-5007 reader (Bio Medic Data Systems). Weight, temperature, and 
physical  observations  of  the  mice  (grooming  habits,  facial  swelling,  secretions,  removal  of  hair, 
respiratory  distress)  were  recorded  daily.  Criteria  for  euthanizing  the  mice  include  open  mouth 
breathing, severity of dyspnea, hypothermia (less than or equal to 30 °C) or weight loss of greater than 
30% of initial body weight. All animal procedures were carried out according to the University of 
Florida Institutional Animal Care and Use Committee guidelines. 
3.9. RFLP Analysis of Vaccinia DNA 
The details of vaccinia virus DNA genomic PCR amplification and RFLP analysis were described 
in [38]. Briefly, 20 set of primers were used to amplify the vaccinia virus DNA and PCR mixtures 
contained ~ 100 ng of viral DNA and 0.25 μg a primer pair in 50 μL of a reaction. Expand Long 
Template  PCR  Kit  (Roche  Molecular  Biologicals,  Indianapolis,  Indiana,  USA)  was  used  with  the 
following conditions: after 2 min at 92 C for DNA denaturing, reaction mixtures were thermocycled 
10 times through successive denaturing (92 C for 10 s), annealing (55 C for 30 s), and elongation 
(68C for 9 min) steps, and then through 20 cycles of denaturing, annealing, and elongation in which 
each  successive  elongation  step  added  20  s.  The  amplicons  were  digested  using  restriction 
endonuclease  BstUI  and  the  digests  were  separated  by  PAGE  using  commercially  available  
pre-cast 4–20% vertical gels (Invitrogen-Novex, Carlsbad, California, USA) run at 110 V for 140 min 
in 40 mM Tris-borate (pH 8.0), 1 mM disodium EDTA (TBE) buffer. The gel images were analyzed 
using the software BioNumerics version 3.5 and the software instructions were used to assess and 
compare RFLP patterns [46]. 
4. Conclusions 
Fowlpox virus has been shown previously to rescue transfected intact and fragmented orthopoxvirus 
genomes by heterologous packaging [4,24,26]. We have shown that transfected genomic vaccinia virus 
DNA can be readily rescued and viable vaccinia virus isolated from cells infected with FPV. The 
background of small plaques predicted to be FPV derived can be further reduced by performing the 
infection/transfection reaction on the mammalian cell line A549 and subsequent plaque purification on 
mammalian cell lines. Furthermore, in cells transfected with intact VV DNA and a PCR fragment 
containing the desired mutation, recombinant VV isolates can be generated at high rates, 21–100%. Viruses 2011, 3                         
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This  method  of  generating  recombinant  viruses  eliminates  the  need  for  selectable  markers  and 
traditional plasmid construction and accelerates the process of generating recombinant viruses. 
While in general, mutants generated via rescue with a host range restricted helper virus such as FPV 
are acceptable for in vitro studies, we have demonstrated that investigators should be cautious in the 
use of these viruses for in vivo studies. In our study, less than 25% of the resulting recombinant viruses 
exhibited a phenotype indistinguishable from that of wtVV when examined in mouse pathogenesis 
studies. Most concerning for this technique but nevertheless interesting in a broader sense is that 33% 
of the viruses isolated were completely apathogenic in mice and exhibited a corresponding increase in 
plaquing  differential  on  CV-1  and  PK-15  cells.  one  isolate  had  almost  no  alteration  in  plaquing 
efficiency in tissue culture but the virus was apathogenic in mice. 
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